MoonLake Immunotherapeutics Receives Unanimous Support for Phase 3 Trial of Sonelokimab in Hidradenitis Suppurativa from FDA and EMA

MoonLake Immunotherapeutics Receives Unanimous Support for Phase 3 Trial of Sonelokimab in Hidradenitis Suppurativa from FDA and EMA Company: MoonLake Immunotherapeutics Indication: Hidradenitis Suppurativa (HS) Drug: Sonelokimab (SLK) Trial Phase: Phase 3 NCT ID: NCT05322473 Overview MoonLake Immunotherapeutics, a clinically-focused biopharmaceutical company, has announced a significant milesto..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

MoonLake Immunotherapeutics Receives Endorsement from FDA and EMA for Phase 3 Program of Sonelokimab in Treating Hidradenitis Suppurativa

MoonLake Immunotherapeutics Receives Endorsement from FDA and EMA for Phase 3 Program of Sonelokimab in Treating Hidradenitis Suppurativa MoonLake Immunotherapeutics, an innovative biopharmaceutical company, has received the green light from key health authorities—the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—for the advancement of their Phase 3 clinical tri..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 27.
  • textsms